• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PRKAR1A 的双重作用：作为癌细胞和癌源性干细胞潜在抗癌靶点。

Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem Cells.

机构信息

Department of Biomedical Laboratory Science, Konyang University, Daejeon 35365, Republic of Korea.

Department of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.

出版信息

Int J Mol Sci. 2024 Mar 1;25(5):2876. doi: 10.3390/ijms25052876.

DOI:10.3390/ijms25052876
PMID:38474121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10932193/
Abstract

The integration of innovative medical technologies and interdisciplinary collaboration could improve the treatment of cancer, a globally prevalent and often deadly disease. Despite recent advancements, current cancer therapies fail to specifically address recurrence and target cancer stem cells (CSCs), which contribute to relapse. In this study, we utilized three types of cancer cells, from which three types of CSCs were further derived, to conduct a proteomic analysis. Additionally, shared cell surface biomarkers were identified as potential targets for a comprehensive treatment strategy. The selected biomarkers were evaluated through short hairpin RNA treatment, which revealed contrasting functions in cancer cells and CSCs. Knockdown of the identified proteins revealed that they regulate the epithelial-mesenchymal transition (EMT) and stemness via the ERK signaling pathway. Resistance to anticancer agents was consequently reduced, ultimately enhancing the overall anticancer effects of the treatment. Additionally, the significance of these biomarkers in clinical patient outcomes was confirmed using bioinformatics. Our study suggests a novel cancer treatment strategy that addresses the limitations of current anticancer therapies.

摘要

创新的医疗技术的整合和跨学科的合作可以改善癌症的治疗，癌症是一种全球性的、常见的、往往是致命的疾病。尽管最近取得了进展，但目前的癌症疗法未能专门解决复发和针对癌症干细胞（CSC）的问题，而 CSC 是导致癌症复发的原因之一。在这项研究中，我们使用了三种癌细胞，进一步从中衍生出三种 CSC，进行了蛋白质组学分析。此外，还确定了共享的细胞表面生物标志物作为综合治疗策略的潜在靶点。通过短发夹 RNA 处理评估了选定的生物标志物，结果表明它们在癌细胞和 CSC 中具有不同的功能。敲除鉴定出的蛋白质表明，它们通过 ERK 信号通路调节上皮-间充质转化（EMT）和干性。因此，抗癌药物的耐药性降低，最终增强了治疗的整体抗癌效果。此外，还使用生物信息学证实了这些生物标志物在临床患者预后中的重要性。我们的研究提出了一种新的癌症治疗策略，解决了当前抗癌疗法的局限性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/bb74d9d1d4f8/ijms-25-02876-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/f3dae0f363f8/ijms-25-02876-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/89bce0acd875/ijms-25-02876-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/f75d8f9b58ba/ijms-25-02876-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/eba63579bd34/ijms-25-02876-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/42ca3dec9e3c/ijms-25-02876-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/19a4f16c6d43/ijms-25-02876-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/00f819b46ce1/ijms-25-02876-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/fa98c86ca3a0/ijms-25-02876-g008a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/db8baaedb34f/ijms-25-02876-g009a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/ad3bfb92348c/ijms-25-02876-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/23074b5ce782/ijms-25-02876-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/e0a82ec68bac/ijms-25-02876-g012a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/36d9f772bcce/ijms-25-02876-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/bb74d9d1d4f8/ijms-25-02876-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/f3dae0f363f8/ijms-25-02876-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/89bce0acd875/ijms-25-02876-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/f75d8f9b58ba/ijms-25-02876-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/eba63579bd34/ijms-25-02876-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/42ca3dec9e3c/ijms-25-02876-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/19a4f16c6d43/ijms-25-02876-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/00f819b46ce1/ijms-25-02876-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/fa98c86ca3a0/ijms-25-02876-g008a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/db8baaedb34f/ijms-25-02876-g009a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/ad3bfb92348c/ijms-25-02876-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/23074b5ce782/ijms-25-02876-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/e0a82ec68bac/ijms-25-02876-g012a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/36d9f772bcce/ijms-25-02876-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8696/10932193/bb74d9d1d4f8/ijms-25-02876-sch001.jpg

相似文献

1
Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem Cells.PRKAR1A 的双重作用：作为癌细胞和癌源性干细胞潜在抗癌靶点。
Int J Mol Sci. 2024 Mar 1;25(5):2876. doi: 10.3390/ijms25052876.
2
Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells.端粒酶逆转录酶促进癌细胞中的上皮-间充质转化和干细胞样特征。
Oncogene. 2013 Sep 5;32(36):4203-13. doi: 10.1038/onc.2012.441. Epub 2012 Oct 8.
3
Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.全面组学分析新型小分子抑制剂对结直肠癌细胞耐药致癌特征的抗肿瘤作用
Cells. 2021 Aug 3;10(8):1970. doi: 10.3390/cells10081970.
4
Stem cell programs in cancer initiation, progression, and therapy resistance.肿瘤起始、进展和治疗抵抗中的干细胞程序。
Theranostics. 2020 Jul 9;10(19):8721-8743. doi: 10.7150/thno.41648. eCollection 2020.
5
Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma.发现血管内皮生长因子受体-2 抑制剂对 CD44+和 CD133+癌症干细胞（CSCs）具有显著的抗癌活性：逆转转化生长因子-β诱导的肝癌上皮-间充质转化（EMT）。
Eur J Med Chem. 2020 Dec 1;207:112851. doi: 10.1016/j.ejmech.2020.112851. Epub 2020 Sep 18.
6
Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.Let-7d miRNA 在骨肉瘤源性 3AB-OS 癌症干细胞中表现出既具有抑癌作用又具有致癌作用。
J Cell Physiol. 2016 Aug;231(8):1832-41. doi: 10.1002/jcp.25291. Epub 2016 Jan 28.
7
Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.低浓度二甲双胍对CD44(+)CD117(+)卵巢癌干细胞上皮-间质转化的抑制作用
Stem Cell Res Ther. 2015 Dec 30;6:262. doi: 10.1186/s13287-015-0249-0.
8
The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells.T 盒转录因子 Brachyury 通过与腺样囊性癌细胞中的癌症干细胞样细胞相关联，调节上皮-间充质转化。
BMC Cancer. 2012 Aug 29;12:377. doi: 10.1186/1471-2407-12-377.
9
ZnAs@SiO nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling.ZnAs@SiO 纳米颗粒作为一种潜在的抗肿瘤药物，通过 SHP-1/JAK2/STAT3 信号通路靶向肝癌中的干性和上皮-间充质转化。
Theranostics. 2019 Jun 9;9(15):4391-4408. doi: 10.7150/thno.32462. eCollection 2019.
10
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.通过BRCA1缺陷型乳腺癌干细胞的白花丹醌选择性作用模式。
BMC Cancer. 2016 May 26;16:336. doi: 10.1186/s12885-016-2372-4.

本文引用的文献

1
Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma.抑制 NANOG 表达可降低脑胶质瘤干细胞的耐药性。
Genes (Basel). 2023 Jun 16;14(6):1276. doi: 10.3390/genes14061276.
2
Active Targeting of Versatile Nanocomplex Using the Novel Biomarker of Breast Cancer Stem Cells.利用乳腺癌干细胞新型标志物主动靶向多功能纳米复合物。
Int J Mol Sci. 2022 Dec 30;24(1):685. doi: 10.3390/ijms24010685.
3
Cancer Stem Cells in Hepatocellular Carcinoma: Intrinsic and Extrinsic Molecular Mechanisms in Stemness Regulation.
肝癌中的肿瘤干细胞：干性调控的内在和外在分子机制。
Int J Mol Sci. 2022 Oct 14;23(20):12327. doi: 10.3390/ijms232012327.
4
Epithelial-Mesenchymal Transition (EMT) 2021.上皮-间质转化（EMT）2021。
Int J Mol Sci. 2022 May 23;23(10):5848. doi: 10.3390/ijms23105848.
5
Lifestyle and Hepatocellular Carcinoma What Is the Evidence and Prevention Recommendations.生活方式与肝细胞癌：证据与预防建议
Cancers (Basel). 2021 Dec 26;14(1):103. doi: 10.3390/cancers14010103.
6
and Thyroid Tumors.以及甲状腺肿瘤。
Cancers (Basel). 2021 Jul 30;13(15):3834. doi: 10.3390/cancers13153834.
7
EMT and Cancer Cell Stemness Associated With Chemotherapeutic Resistance in Esophageal Cancer.上皮-间质转化和癌细胞干性与食管癌化疗耐药性相关
Front Oncol. 2021 Jun 3;11:672222. doi: 10.3389/fonc.2021.672222. eCollection 2021.
8
Drug resistance and Cancer stem cells.耐药性和癌症干细胞。
Cell Commun Signal. 2021 Feb 15;19(1):19. doi: 10.1186/s12964-020-00627-5.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
EMT imparts cancer stemness and plasticity: new perspectives and therapeutic potential.上皮-间质转化赋予癌症干性和可塑性：新观点与治疗潜力
Front Biosci (Landmark Ed). 2021 Jan 1;26(2):238-265. doi: 10.2741/4893.